TY - JOUR A1 - Stadion, Mandy A1 - Schürmann, Annette T1 - Intermittent fasting T1 - Intermittierendes Fasten BT - What effects does it have in humans? BT - Welche Effekte hat es beim Menschen? JF - Psychotherapeut N2 - A long-term positive energy balance leads to overweight and obesity. Adiposity is the main risk factor for cardiovascular diseases, type 2 diabetes and cancer and is often accompanied by depression. The increasing prevalence creates a major problem for the healthcare system. The conservative management of obesity strives for weight loss by reducing the daily caloric intake and increasing physical activity as well as an improvement in the quality of life supported by psychological interventions. For reducing body weight, intermittent fasting represents an alternative to continuous calorie restriction as it can be easily integrated into daily life. In this form of diet calorie intake is limited in time, i.e. on 2 days in the week or 6-10 h per day. Animal and human studies provide evidence that intermittent fasting over a longer time period is a suitable method to decrease body fat and to improve many metabolic parameters. Fasting alters metabolism and activates specific cellular pathways. These have not only cardioprotective effects but also neuroprotective and antidepressive effects. In this article the currently discussed mechanisms induced by intermittent fasting are highlighted and the essential observations from randomized controlled human trials are presented. KW - Obesity KW - Brain-derived neurotrophic factor KW - Insulin sensitivity KW - Metabolic flexibility KW - Circadian rhythm Y1 - 2020 U6 - https://doi.org/10.1007/s00278-020-00471-5 SN - 0935-6185 SN - 1432-2080 VL - 66 IS - 1 SP - 23 EP - 27 PB - Springer CY - New York ER - TY - JOUR A1 - Stadion, Mandy A1 - Schürmann, Annette T1 - Intermittierendes Fasten BT - was gibt es Neues aus der Wissenschaft? BT - what’s new from science? JF - Der Diabetologe N2 - Obesity increases the risk of metabolic disorders and can lead to type 2 diabetes. Therefore, the treatment and prevention of obesity represent important medical challenges. Increased physical activity and a reduction in daily caloric intake of 25-30% are often recommended. Another possibility is intermittent fasting, by limiting dietary caloric content over certain times, i.e. one or more days a week or for more than 14 h a day. Animal and human studies provide evidence that intermittent fasting in obesity leads to a reduction in body fat mass as well as to improvements of metabolic parameters and insulin sensitivity. These positive effects are mediated not only by the decrease in body mass, but also by the activation of metabolic pathways and cellular processes that are specific for fasting conditions. In this article, we describe the current knowledge about the mechanisms induced by intermittent fasting and present results from randomized controlled human trials. N2 - Übergewicht und Adipositas erhöhen die Risiken für Stoffwechselstörungen und können zu einem Typ-2-Diabetes führen. Deshalb stellen die Behandlung und Prävention von Fettleibigkeit eine große medizinische Herausforderung dar. Häufig werden eine erhöhte körperliche Aktivität und die Reduktion der täglichen Kalorienaufnahme um 25–30 % angeraten. Eine andere Möglichkeit bietet intermittierendes Fasten, also eine Kalorieneinschränkung über bestimmte Zeiten, d. h. an einem oder mehreren Tagen pro Woche oder über mehr als 14 h pro Tag. Tier- und Humanstudien lieferten Hinweise darauf, dass intermittierendes Fasten bei Adipositas zu einer Verringerung der Körperfettmasse sowie zu Verbesserungen der Stoffwechselparameter und der Insulinsensitivität führt. Diese positiven Effekte werden nicht nur allein durch die Abnahme der Körpermasse, sondern auch durch die Aktivierung von Stoffwechselwegen und zellulären Prozessen ausgelöst, die für Fastenbedingungen spezifisch sind. In diesem Artikel beschreiben wir die derzeit bekannten Mechanismen, die durch intermittierendes Fasten induziert werden, und stellen Ergebnisse aus randomisierten kontrollierten Studien am Menschen vor. T2 - Intermittent fasting KW - Glucose metabolism disorders KW - Lipid metabolism KW - Insulin sensitivity KW - Energy metabolism KW - Circadian rhythm KW - Glukosestoffwechselstörungen KW - Fettstoffwechsel KW - Insulinsensitivität KW - Energiestoffwechsel KW - Zirkadianer Rhythmus Y1 - 2020 U6 - https://doi.org/10.1007/s11428-020-00666-z SN - 1860-9716 SN - 1860-9724 VL - 16 IS - 7 SP - 641 EP - 646 PB - Springer Medizin CY - Berlin ER -